Navigation Links
Chimerix's Antiviral CMX157 Demonstrates Positive Phase 1 Clinical Results With Favorable Pharmacokinetics, Safety and Tolerability
Date:12/13/2010

the treatment of HIV and other applications, including its potential to address XMRV associated with chronic fatigue syndrome," said Kenneth I. Moch, President and Chief Executive Officer of Chimerix.  "We believe CMX157 holds promise as a highly competitive anti-HIV agent, suitable for combination regimens, with a favorable pharmacokinetic and tolerability profile, and potential for once-weekly dosing.  Further, we have intriguing in vitro data showing our PIM Conjugate Technology may facilitate CMX157 access across the blood-brain barrier to address latent retrovirus in compartments that otherwise have proven to be inaccessible by conventional anti-HIV agents.  There's a significant need for new HIV therapies to help refractory and inadequately treated patients, and our next step is to evaluate CMX157 in HIV patients."

CMX157 Phase 1 Clinical Trial Results

CMX157 is a new chemical entity created by applying Chimerix's PIM (Phospholipid IntramembraneMicrofluidization) Conjugate Technology to chemically modify tenofovir, the molecule underlying the prodrug Viread®, an antiviral agent approved for the treatment of human immunodeficiency virus (HIV) and chronic hepatitis B. The CMX157 Phase 1 clinical study was a randomized, blinded, dose-escalation trial to evaluate safety, tolerability and pharmacokinetics.  Healthy volunteers received a single dose ranging from 25 mg to 400 mg of CMX157 or a standard dose of Viread for comparison of intracellular levels of the active antiviral, tenofovirdiphosphate (TFV-PP). CMX157 was well tolerated and there were no laboratory, vital sign, electrocardiogram changes or adverse event trends attributable to drug. In addition, plasma concentrations of CMX157 increased linearly with dose and target plasma levels were attained. The active antiviral, TFV-PP, was measurable in peripheral blood mononuclear cells (PBMC) from all patients after a single 400 mg dose of CMX
'/>"/>

SOURCE Chimerix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. R7128 Demonstrates Safety and Potent Antiviral Activity in HCV-Infected Patients
2. Trana Discovery and Southern Research Institute Announce the First RNA-RNA High Throughput Drug Screening Assay Platform for HIV Antivirals
3. Roches Investigational Polymerase Inhibitor, Combined with PEGASYS(R) and COPEGUS(TM), Shows Potent Antiviral Activity in Treatment of Chronic Hepatitis C at Four Weeks
4. Anadys Pharmaceuticals Presents Data on ANA598, a Non-Nucleoside Inhibitor of the HCV Polymerase, at the 21st International Conference on Antiviral Research
5. BARACLUDE(R) (Entecavir) Treatment Resulted In Greater Viral Load Suppression Compared to Adefovir at 96 Weeks In Antiviral-Naive Adult Chronic Hepatitis B E-Antigen Positive Patients
6. ViroDefense Inc Announces Selection of Poliovirus Antiviral Preclinical Candidate
7. Positive Phase I/II Data of IDX899 Confirm Potent Antiviral Activity and Favorable Safety Profile in Treatment-Naive HIV-Infected Patients
8. Ardea Biosciences Presents Phase 2a Antiviral Activity Data for Lead HIV Candidate, RDEA806 at XVII International AIDS Conference
9. Roche, InterMune and Pharmasset Announce Initiation of INFORM-1, the First Dual-Combination Clinical Trial with Oral Antivirals in Hepatitis C
10. ANA598 Demonstrates Potent Antiviral Activity in an Early Clinical Study in HCV-Infected Patients
11. ANA598 Demonstrates Potent Antiviral Activity at all Dose Levels in Completed Phase Ib Study in Hepatitis C Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... Aug. 1, 2014 Research and ... "Global Medical Biosensors Market 2014-2018" report ... http://photos.prnewswire.com/prnh/20130307/600769 Medical biosensors are used ... physicochemical detectors. These biosensors monitor health status, disease ... non-invasive methods. They are cost-effective and user-friendly devices. ...
(Date:8/1/2014)... and PALO ALTO, Calif. , Aug. ... Inc. (CFRI) today announced a partnership to expand awareness ... community through the CFChef Shares program. CFChef Shares will ... part of AbbVie,s CFChef program – an online resource ... to maintain a healthy diet by submitting recipes to ...
(Date:8/1/2014)... DALLAS , August 1, 2014 ... Care Market by Type (Traditional Wound Closure, Anti infective), ... Active (Artificial Skin & Skin Substitutes), Pressure Relief ... by MarketsandMarkets, the global Wound Care Market is expected ... Billion in 2014, growing at a CAGR of ...
Breaking Medicine Technology:Global Medical Biosensors Market 2014-2018: Key Vendors are Abbott, Bayer, LifeScan and F. Hoffmann-La Roche 2AbbVie and Cystic Fibrosis Research, Inc. (CFRI) Team Up to Raise Awareness of the Nutritional Needs of CF Patients through the CFChef Shares Program 2AbbVie and Cystic Fibrosis Research, Inc. (CFRI) Team Up to Raise Awareness of the Nutritional Needs of CF Patients through the CFChef Shares Program 3Wound Care Market Worth $18.3 Billion by 2019 2Wound Care Market Worth $18.3 Billion by 2019 3
(Date:8/1/2014)... 2014 Lifeinsurancenomedicalexam.info has released a ... for clients who have high cholesterol levels. , ... and qualify for no medical exam life insurance. These ... background medical check-ups. , Since there are no medical ... will qualify in just a few minutes. However, this ...
(Date:8/1/2014)... According to Forrester Research, more than 90 percent ... search of information, and thanks to the launching of DCInsurers ... and resources on insurance specifically for the state of Colorado ... next step in the growth of our business,” Doug King, ... Commercial Insurance Resources office. “We recognize that the web is ...
(Date:8/1/2014)... (PRWEB) August 01, 2014 Chilton ... portal that aims to empower patients and their ... their health care by providing easy, secure access ... gives patients instant, web-based access to their health ... radiology results, medications, allergies, demographic information, visit history, ...
(Date:8/1/2014)... Ohio (PRWEB) August 01, 2014 Home ... care for seniors, is honored to be recognized as a ... award is given to home care providers who rank in ... categories, based on monthly satisfaction interviews conducted by Home Care ... the leading home care businesses, the best of the best!” ...
(Date:8/1/2014)... August 01, 2014 Frontier Nursing University ... and Services Administration’s Advanced Education Nursing Traineeship (AENT) ... provide direct support to 280 students over the grant ... Program is to increase the number of advanced education ... nursing faculty to address the nurse faculty shortage that ...
Breaking Medicine News(10 mins):Health News:No Exam Life Insurance - Coverage for Clients Who Have High Cholesterol 2Health News:DCInsurers Agent Doug King Launches a New Website 2Health News:DCInsurers Agent Doug King Launches a New Website 3Health News:Chilton Medical Center Launches Online Patient Portal 2Health News:Cincinnati Senior Care Company Receives 2014 Best of Home Care® Employer of Choice Award 2Health News:Frontier Nursing University Receives $700,000 in Scholarships for Advanced Practice Nursing and Midwifery Students 2
... evaluating their risk for heart disease are missing a crucial ... University of Rochester Medical Center study published in the June ... that most doctors use to assess risk, known as Framingham ... of low income and/or less than a high school education ...
... , 2009 marks sixth consecutive year of support , ... Inc. announced today that the company has committed to raise ... Walk." The commitment represents the sixth consecutive year of ... , , "Safety-Kleen is firmly committed to its financial ...
... ... ... Sturchio, Chairman, Corporate Council on Africa, and Incoming President, Global Health Council ,Ms. Joan ... Department of State ,Dr. Kate Tulenko, Health Specialist, Coordinator of the Africa Health Workforce ...
... 16 The American Association of Oral ... (D-LA) on introducing S. 1235, the Senate companion ... and Surgery (CARES) Act . The bill would require ... Employee Retirement Income Security Act (ERISA) , ...
... Provide Personal Guide to Help Local Cancer Patients Better ... , , PHILADELPHIA, June 16 The ... at the Kimmel Cancer Center at Jefferson in Philadelphia, ... is the first site to launch in Pennsylvania as ...
... Inventive and Earth-friendly fibers are available to solve customers, needs ... ANSONVILLE, N.C., June 16 "Perpetual Innovation" should bring to ... products but also its process. That,s what Premiere Fibers does. ... www.premierefibers.com as well as a whole ...
Cached Medicine News:Health News:Income, education, important factors in heart disease risk 2Health News:Safety-Kleen Announces $100,000 Commitment to American Heart Association 'Start! Dallas Heart Walk' 2Health News:Building Healthcare Leadership in Africa: A Call to Action 2Health News:Oral and Maxillofacial Surgeons Applaud Senator Mary Landrieu (D-LA) For Introducing Legislation to Require Insurance Coverage for Children With Congenital Deformities 2Health News:Philadelphia Cancer Patients to Benefit from Expansion of the American Cancer Society Patient Navigator Program 2Health News:Philadelphia Cancer Patients to Benefit from Expansion of the American Cancer Society Patient Navigator Program 3Health News:Philadelphia Cancer Patients to Benefit from Expansion of the American Cancer Society Patient Navigator Program 4Health News:Philadelphia Cancer Patients to Benefit from Expansion of the American Cancer Society Patient Navigator Program 5Health News:Premiere Fibers Unveils New Logo, Names for Innovative Brands 2
For the quantitative determination of Alanine Aminotransferase in serum. Optimized IFCC without P-5'-P, Linearity: 500 IU/L at 37 C. Liquid Working Reagent prepared with simple 1:9 dilution....
Intended for the quantitative determination of total protein in serum. Reaction: endpoint. Wavelength: 540 nm. Linearity: 12 g/dL (120 g/L). Ready to use liquid reagent....
Urea nitrogen (BUN) liquid reagent is used for the kinetic quantitative determination of Urea Nitrogen (BUN) in human serum used in routine examination and monitoring of therapy and relapses....
For the direct colorimetric determination of Urea Nitrogen (BUN) in human serum or plasma....
Medicine Products: